Skip to content
★ Sign in to follow
Tianjin Chase Sun Pharmaceutical Co.,Ltd logo

Tianjin Chase Sun Pharmaceutical Co.,Ltd Stock: price and insider trades · China

红日药业

CN·Mcap CN¥9.5BHealth Care

Tianjin Chase Sun Pharmaceutical Co.,Ltd: what insiders have been doing

Every trade that managers of Tianjin Chase Sun Pharmaceutical Co.,Ltd disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Health Care sector. Tianjin Chase Sun Pharmaceutical Co.,Ltd has had no insider filing for more than a year; the last one goes back to 23 May 2023.

The full history, which starts in 2021, counts no purchases against 17 sales.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and Vetoquinol SA. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.

Insider Decl.
17
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€28M
17 ops. · all time

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 17,094 of 26,911 companies
42.9
score / 100
Value
40
Quality
45
FCF yld6.9%
Earn yld0.2%
EV/EBITDA23.3x
ROE0.2%
Gross mgn53%
Net mgn0.4%
Debt/EBITDA1.9x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2024

FY ended December 2024 · cache

CN¥3.17
Analyst consensus
1 analysts
·
CN¥3.00Target CN¥3.00(-5%)CN¥3.00
Income statement
RevenueCN¥5.8B
Gross profitCN¥3.1B53% margin
EBITDACN¥445.5M8% margin
Net incomeCN¥21.5M0.4% margin
Valuation
PER (trailing)317.0x
P/Book1.1x
Beta0.02
Balance sheet & cash
Market capCN¥9.5B
Total debtCN¥852.1M
Free Cash FlowCN¥659.1M
Debt / Equity4%
Profitability & ownership
ROE0.2%
ROA1.1%
% insiders42.4%
% institutions1.6%
Last declaration on 23 May 2023
Declarations17 total
  • ▼
    董事Executives
    29M CNY8SZSE
    5,000,000 shares13.9% of flowA股XSHESZSE:173000006614180260
  • ▼
    董事Executives
    15M CNY8SZSE
    2,300,000 shares7.5% of flowA股XSHESZSE:173000006282518050
  • ▼
    董事Executives
    6M CNY7SZSE
    999,900 shares3.2% of flowA股XSHESZSE:173000006264759740
  • ▼
    董事Executives
    20M CNY8SZSE
    3,005,700 shares9.6% of flowA股XSHESZSE:173000006108880060
  • ▼
    董事Executives
    80,344 CNY7SZSE
    12,100 shares0.0% of flowA股XSHESZSE:173000006080902200
  • ▼
    董事Executives
    70,900 CNY7SZSE
    10,000 shares0.0% of flowA股XSHESZSE:173000005992969200
  • ▼
    董事Executives
    243,820 CNY7SZSE
    36,500 shares0.1% of flowA股XSHESZSE:173000005720876260
  • ▼
    董事Executives
    5M CNY7SZSE
    700,000 shares2.5% of flowA股XSHESZSE:173000005704023330
  • ▼
    董事Executives
    4M CNY7SZSE
    635,500 shares2.2% of flowA股XSHESZSE:173000005700821820
  • ▼
    董事Executives
    4M CNY7SZSE
    620,000 shares2.3% of flowA股XSHESZSE:173000005689829470
  • ▼
    董事Executives
    945,600 CNY7SZSE
    120,000 shares0.5% of flowA股XSHESZSE:173000005652389200
  • ▼
    董事Executives
    23M CNY8SZSE
    3,710,000 shares11.9% of flowA股XSHESZSE:173000005607954800
  • ▼
    董事Executives
    25M CNY8SZSE
    4,200,000 shares12.7% of flowA股XSHESZSE:173000005605692400
  • ▼
    董事Executives
    10M CNY8SZSE
    1,700,000 shares5.1% of flowA股XSHESZSE:173000005585460640
  • ▼
    副总经理Executives
    2M CNY30SZSE
    225,900 shares100.0% of flowA股XSHESZSE:173000005210097920
  • ▼
    董事Executives
    10M CNY7SZSE
    2,353,000 shares4.8% of flowA股XSHESZSE:173000004904940320
  • ▼
    董事Executives
    50M CNY9SZSE
    12,500,000 shares23.7% of flowA股XSHESZSE:173000004577012930

17 of 17 declarations

About Tianjin Chase Sun Pharmaceutical Co.,Ltd

红日药业 is a company in the health and pharmaceutical sector, listed on the XSHE market. It focuses on the research, development, and production of medicines and pharmaceutical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations